Peripheral blood microRNA and VEGFA mRNA changes following electroconvulsive therapy: implications for psychotic depression.
Loading...
Authors
Kolshus, E
Ryan, K M
Blackshields, G
Smyth, P
Sheils, O
McLoughlin, D M
Issue Date
2017-10-04
Type
Journal Article
Randomized Controlled Trial
Randomized Controlled Trial
Language
en
Keywords
VEGF , depression , electroconvulsive therapy , microRNAs , psychotic mood disorders
Alternative Title
Abstract
MicroRNAs are short, non-coding molecules that regulate gene expression. Here, we investigate the role of microRNAs in depression and electroconvulsive therapy (ECT).
We performed three studies: a deep sequencing discovery-phase study of miRNA changes in whole blood following ECT (n = 16), followed by a validation study in a separate cohort of patients pre-/post-ECT (n = 37) and matched healthy controls (n = 34). Changes in an experimentally validated gene target (VEGFA) were then analysed in patients pre-/post-ECT (n = 97) and in matched healthy controls (n = 53).
In the discovery-phase study, we found no statistically significant differences in miRNA expression from baseline to end of treatment in the group as a whole, but post hoc analysis indicated a difference in patients with psychotic depression (n = 3). In a follow-up validation study, patients with psychotic depression (n = 7) had elevated baseline levels of miR-126-3p (t = 3.015, P = 0.006) and miR-106a-5p (t = 2.598, P = 0.025) compared to healthy controls. Following ECT, these differences disappeared. Baseline VEGFA levels were significantly higher in depressed patients compared to healthy controls (F(1,144) = 27.688, P = <0.001). Following ECT, there was a significant change in VEGFA levels in the psychotic group only (t = 2.915, P = 0.010).
Molecular differences (miRNA and VEGFA) may exist between psychotic and non-psychotic depression treated with ECT.
We performed three studies: a deep sequencing discovery-phase study of miRNA changes in whole blood following ECT (n = 16), followed by a validation study in a separate cohort of patients pre-/post-ECT (n = 37) and matched healthy controls (n = 34). Changes in an experimentally validated gene target (VEGFA) were then analysed in patients pre-/post-ECT (n = 97) and in matched healthy controls (n = 53).
In the discovery-phase study, we found no statistically significant differences in miRNA expression from baseline to end of treatment in the group as a whole, but post hoc analysis indicated a difference in patients with psychotic depression (n = 3). In a follow-up validation study, patients with psychotic depression (n = 7) had elevated baseline levels of miR-126-3p (t = 3.015, P = 0.006) and miR-106a-5p (t = 2.598, P = 0.025) compared to healthy controls. Following ECT, these differences disappeared. Baseline VEGFA levels were significantly higher in depressed patients compared to healthy controls (F(1,144) = 27.688, P = <0.001). Following ECT, there was a significant change in VEGFA levels in the psychotic group only (t = 2.915, P = 0.010).
Molecular differences (miRNA and VEGFA) may exist between psychotic and non-psychotic depression treated with ECT.
Description
Citation
Kolshus, E., Ryan, K. M., Blackshields, G., Smyth, P., Sheils, O., & McLoughlin, D. M. (2017). Peripheral blood microRNA and VEGFA mRNA changes following electroconvulsive therapy: implications for psychotic depression. Acta psychiatrica Scandinavica, 136(6), 594–606. https://doi.org/10.1111/acps.12821
Publisher
License
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Journal
Acta psychiatrica Scandinavica
Volume
136
Issue
6
PubMed ID
ISSN
1600-0447